Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evolus (EOLS) Research & Development (2017 - 2026)

Evolus filings provide 9 years of Research & Development readings, the most recent being $2.2 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 1.27% to $2.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.6 million, a 3.2% increase, with the full-year FY2025 number at $9.6 million, up 4.4% from a year prior.
  • Research & Development hit $2.2 million in Q1 2026 for Evolus, down from $3.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.5 million in Q4 2025 to a low of $468000.0 in Q1 2022.
  • Median Research & Development over the past 5 years was $2.0 million (2025), compared with a mean of $1.9 million.
  • The widest YoY moves for Research & Development: up 357.14% in 2022, down 44.35% in 2022.
  • Evolus' Research & Development stood at $1.3 million in 2022, then skyrocketed by 76.56% to $2.4 million in 2023, then grew by 2.1% to $2.4 million in 2024, then surged by 43.25% to $3.5 million in 2025, then plummeted by 35.65% to $2.2 million in 2026.
  • The last three reported values for Research & Development were $2.2 million (Q1 2026), $3.5 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.